Peel Hunt reaffirmed their buy rating on shares of Sinclair Pharma (LON:SPH) in a research report report published on Wednesday morning.
Separately, Numis Securities reiterated a hold rating and issued a GBX 21 ($0.29) target price on shares of Sinclair Pharma in a report on Thursday, February 22nd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of GBX 46.40 ($0.65).
LON SPH opened at GBX 18.43 ($0.26) on Wednesday. Sinclair Pharma has a 12 month low of GBX 20.50 ($0.29) and a 12 month high of GBX 36.12 ($0.51).
In other news, insider Chris Spooner purchased 200,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were acquired at an average price of GBX 23 ($0.32) per share, for a total transaction of £46,000 ($64,570.47).
COPYRIGHT VIOLATION NOTICE: “Sinclair Pharma (SPH) Receives “Buy” Rating from Peel Hunt” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/sinclair-pharma-sph-receives-buy-rating-from-peel-hunt.html.
About Sinclair Pharma
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.
Receive News & Ratings for Sinclair Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma and related companies with MarketBeat.com's FREE daily email newsletter.